Key Developments for Krystal Biotech, Inc. ($KRYS):
-
CEO Compensation Decrease: CEO Krish S. Krishnan’s compensation for 2025 is reported at $10.44 million, down 49.4% from $15.60 million in 2024, according to a new SEC filing.
-
Insider Trading Activity: Over the past six months, $KRYS insiders have engaged in 84 stock sales without any purchases, totaling significant shares sold. Noteworthy sales include Krishnan and other executives selling large quantities.
-
Institutional Investor Movements: In the most recent quarter, 173 institutional investors added $KRYS to their portfolios while 135 reduced their positions. Major moves include UBS AM drastically reducing its shares by 95.9%.
-
Analyst Ratings and Price Targets: Wall Street analysts show optimism with three buy ratings issued recently, and a median price target of $320.5 based on eight recent targets that range up to $371.
These developments indicate a complex picture of company performance and sentiment among insiders and institutional investors.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.quiverquant.com/news/Krystal+Biotech%2C+Inc.+%28%24KRYS%29+CEO+2025+Pay+Revealed
